Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (3043)	7/19/2010 12:19:22 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

NEXMD was up 11.45% at 11:17 am but is up only 5.88% at present.<g Volume is about 0.23x its ADV The stock is trying to find support at the $3.25 level in spite of its larger losses and lower revenues.<g> bigcharts.marketwatch.com NEXMD has a pipeline of drug candidates based on its NexACT technology. It has announced that it will present data of PrevOnco at the International Liver Cancer Association 4th Annual Conference in Sept in Montreal. PrevOnco is NexMed’s drug for treatment of patients with advanced, unresectable hepatocellular Cas and it was granted orphan drug status by the FDA back in 2008. In March NexMed filed an IND for PrevOnco and in April the FDA gave it an OK to test the product in a PII as a first line therapy for HCC. In the same IND,the FDA also gave it the opportunity to move PrevOnco directly into a PIII that would support marketing approval, subject to positive study results. NexMed would need to use PrevOnco in combination with Doxorubicin as a second-line therapy for patients who have failed NEXAVAR, which is the current first-line anticancer treatment for patients with either HCC or advanced renal cell The ACTAY is $1 <g> On July 7 the NAZ gave NEXMD an OK for continued listing.<g> Over the years NEXMD has burned a good amount of $$$ <g> I will not put a TT at present, but would keep the stock on a WL pending future developmengts. The stock has room to run with some good news.<g> bigcharts.marketwatch.com Bernard